Table 1.
Baseline demographics and disease characteristics of patients in the tofacitinib dose de‐escalation and dose escalation subpopulations of OCTAVE Open
| Tofacitinib maintenance remitter dose de‐escalation subpopulation (N = 66) | Tofacitinib maintenance failure dose escalation subpopulation (N = 57) | |
|---|---|---|
| Age (y), mean (SD) | 45.6 (15.1) | 39.8 (12.5) |
| Male, n (%) | 32 (48.5) | 24 (42.1) |
| Mean body mass index, kg/m2 (SD) | 25.7 (4.4) | 25.0 (5.4) |
| Total Mayo score at baseline of OCTAVE Open, mean (SD) | 1.1 (0.8) | 9.1 (1.6) |
| Disease duration, n (%)a | ||
| <6 y | 32 (48.5) | 28 (49.1) |
| ≥6 y | 34 (51.5) | 29 (50.9) |
| Corticosteroid use at baseline of OCTAVE Open, n (%) | 1 (1.5) | 4 (7.0) |
| Prior corticosteroid failure, n (%)a | 52 (78.8) | 44 (77.2) |
| Prior immunosuppressant failure, n (%)a | 43 (65.2) | 51 (89.5) |
| Prior tumour necrosis factor inhibitor failure, n (%)a | 27 (40.9) | 28 (49.1) |
| Extent of disease, n (%)a | ||
| Proctosigmoiditis | 16 (24.6) | 7 (12.3) |
| Left‐sided colitis | 22 (33.8) | 20 (35.1) |
| Extensive colitis/pancolitis | 27 (41.5) | 30 (52.6) |
Abbreviations: N, number of evaluable patients; n, number of patients; SD, standard deviation; y, years.
a
Data at baseline of induction studies.